Mark Smith, Finch CEO

FDA lifts hold on Finch’s mi­cro­bio­me crap­sule, as com­pa­ny looks to right ship

Finch Ther­a­peu­tics’ lead pro­gram may fly again.

The mi­cro­bio­me com­pa­ny an­nounced Thurs­day that the FDA lift­ed a two-month hold on clin­i­cal tri­als for its ex­per­i­men­tal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.